Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 billion ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc.

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...